From Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Washington/Seattle Cancer Care Alliance; Memorial Sloan Kettering Cancer Center; Moffitt Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; University of Michigan Comprehensive Cancer Center; Fox Chase Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; Stanford Cancer Institute; The University of Texas MD Anderson Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Huntsman Cancer Institute at the University of Utah; City of Hope Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred & Pamela Buffett Cancer Center; Stanford Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Duke Cancer Institute; UC San Diego Moores Cancer Center; and National Comprehensive Cancer Network.
J Natl Compr Canc Netw. 2015 Apr;13(4):395-404; quiz 404. doi: 10.6004/jnccn.2015.0055.
The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical Cancer Panel's discussion and major guideline updates from 2014 and 2015. The recommended systemic therapy options for recurrent and metastatic cervical cancer were amended upon panel review of new survival data and the FDA's approval of bevacizumab for treating late-stage cervical cancer. This article outlines relevant data and provides insight into panel decisions regarding various combination regimens. Additionally, a new section was added to provide additional guidance on key principles of evaluation and surgical staging in cervical cancer. This article highlights 2 areas of active investigation and debate from this new section: sentinel lymph node mapping and fertility-sparing treatment approaches.
NCCN 宫颈癌指南为宫颈癌的治疗提供了跨学科的建议。这些 NCCN 指南见解总结了 NCCN 宫颈癌专家组 2014 年和 2015 年的讨论和主要指南更新。在专家组审查新的生存数据和 FDA 批准贝伐单抗治疗晚期宫颈癌后，对复发性和转移性宫颈癌的推荐系统治疗选择进行了修订。本文概述了相关数据，并深入了解了专家组关于各种联合治疗方案的决策。此外，还增加了一个新的章节，就宫颈癌评估和手术分期的关键原则提供额外的指导。本文重点介绍了这个新章节中两个正在积极研究和讨论的领域：前哨淋巴结绘图和保留生育力的治疗方法。
